Erasca, Inc. Common Stock ERAS
i
Market datapartial · fetched 2026-11-12T00:52:24.466Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:10:12.644195673Z
FundamentalsAlpha Vantage · unavailable
Erasca, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 21.37 | 150.3% | 28.1% | 14.32 | 152.3% | 18.8% |
| 25Δ | 20.24 | 140.0% | 22.0% | 14.85 | 157.2% | 16.9% |
| 30Δ | 19.65 | 143.9% | 19.5% | 15.43 | 149.8% | 14.3% |
| 35Δ | 19.18 | 151.8% | 17.9% | 16.02 | 138.5% | 11.6% |
| 40Δ | 18.62 | 149.2% | 15.4% | 16.52 | 143.3% | 10.4% |
| 45Δ | 17.98 | 139.7% | 12.3% | 17.02 | 148.1% | 9.3% |
| 50Δ | 17.39 | 132.3% | 9.7% | |||
| 55Δ | 16.95 | 131.3% | 8.3% | |||
| 60Δ | 16.51 | 130.3% | 6.9% | |||
| 65Δ | 16.06 | 129.4% | 5.5% | |||
| 70Δ | 15.49 | 140.4% | 4.8% | |||
| 75Δ | ||||||
| 80Δ | 28.88 | 313.1% | 4.2% | |||
20Δ
- Pseudo strike
- 21.37
- IV
- 150.3%
- B/E move
- 28.1%
- Pseudo strike
- 14.32
- IV
- 152.3%
- B/E move
- 18.8%
25Δ
- Pseudo strike
- 20.24
- IV
- 140.0%
- B/E move
- 22.0%
- Pseudo strike
- 14.85
- IV
- 157.2%
- B/E move
- 16.9%
30Δ
- Pseudo strike
- 19.65
- IV
- 143.9%
- B/E move
- 19.5%
- Pseudo strike
- 15.43
- IV
- 149.8%
- B/E move
- 14.3%
35Δ
- Pseudo strike
- 19.18
- IV
- 151.8%
- B/E move
- 17.9%
- Pseudo strike
- 16.02
- IV
- 138.5%
- B/E move
- 11.6%
40Δ
- Pseudo strike
- 18.62
- IV
- 149.2%
- B/E move
- 15.4%
- Pseudo strike
- 16.52
- IV
- 143.3%
- B/E move
- 10.4%
45Δ
- Pseudo strike
- 17.98
- IV
- 139.7%
- B/E move
- 12.3%
- Pseudo strike
- 17.02
- IV
- 148.1%
- B/E move
- 9.3%
50Δ
- Pseudo strike
- 17.39
- IV
- 132.3%
- B/E move
- 9.7%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 16.95
- IV
- 131.3%
- B/E move
- 8.3%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 16.51
- IV
- 130.3%
- B/E move
- 6.9%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 16.06
- IV
- 129.4%
- B/E move
- 5.5%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 15.49
- IV
- 140.4%
- B/E move
- 4.8%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 28.88
- IV
- 313.1%
- B/E move
- 4.2%
Options history
Table
| Date | IV (%) |
|---|---|
| 102.06% | |
| 100.58% | |
| 99.47% | |
| 112.66% | |
| 121.23% | |
| 94.53% | |
| 92.50% | |
| 93.71% | |
| 91.44% | |
| 92.18% | |
| 92.61% | |
| 95.29% | |
| 95.37% | |
| 91.28% | |
| 94.24% | |
| 89.34% | |
| 97.35% | |
| 92.25% | |
| 102.37% | |
| 98.87% | |
| 102.41% | |
| 99.41% | |
| 97.74% | |
| 89.72% | |
| 91.93% | |
| 93.26% | |
| 90.98% | |
| 95.58% | |
| 98.58% | |
| 101.42% | |
| 103.56% | |
| 103.38% | |
| 99.48% | |
| 101.64% | |
| 103.93% | |
| 118.97% | |
| 109.44% | |
| 115.39% | |
| 113.69% | |
| 121.90% | |
| 103.73% | |
| 101.07% | |
| 101.88% | |
| 102.36% | |
| 108.58% | |
| 98.46% | |
| 108.44% | |
| 106.64% | |
| 106.98% | |
| 109.83% | |
| 113.85% |
Biotechnology
EVMN
Evommune, Inc. is an innovative biotechnology company focused on developing cutting-edge therapeutics for immunological disorders, targeting significant unmet medical needs in…
More →EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The company is headquartered in Boulder, Colorado.
More →EXEL
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The…
More →EYPT
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China, and the United…
More →FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is…
More →FDMT
Description unavailable
More →